Cancer Research Infection and Cancer: Biology, Therapeutics, and Prevention  AACR Conference on Molecular Diagnostics - 2008
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 11, 216-220, March 1, 1951]
© 1951 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dauben, W. G.
Right arrow Articles by Mabee, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dauben, W. G.
Right arrow Articles by Mabee, D.

A Study of the Metabolism of 20-Methylcholanthrene*

William G. Dauben and Dorothea Mabee

(From the Department of Chemistry and the Radiation Laboratory of the University of California, Berkeley, Calif.)

20-Methylcholanthrene, labeled in the 11-position, has been administered subcutaneously in tricaprylin, and the distribution of radioactivity in the mice at various intervals has been determined. The radioactivity is eliminated mainly in the feces and to a lesser extent in the urine. An appreciable quantity of radioactivity is found in the tumors, part of which is the original hydrocarbon. There appears to be no localization of activity in any tissue or organ, the major amount remaining at the site of injection. The rate of elimination of C14 when introduced in methylcholanthrene appears to be about 3 times as rapid as when it is injected in the form of dibenzanthracene.

* Presented at the Meeting of the American Association for Cancer Research, Inc., in Detroit, April, 1949.

Received 11/20/51.





HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1951 by the American Association for Cancer Research.